These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 20690643)

  • 1. Investigation of the histamine H3 receptor binding site. Design and synthesis of hybrid agonists with a lipophilic side chain.
    Ishikawa M; Watanabe T; Kudo T; Yokoyama F; Yamauchi M; Kato K; Kakui N; Sato Y
    J Med Chem; 2010 Sep; 53(17):6445-56. PubMed ID: 20690643
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of 4-(1H-imidazol-4(5)-ylmethyl)pyridine (immethridine) as a novel, potent, and highly selective histamine H(3) receptor agonist.
    Kitbunnadaj R; Zuiderveld OP; Christophe B; Hulscher S; Menge WM; Gelens E; Snip E; Bakker RA; Celanire S; Gillard M; Talaga P; Timmerman H; Leurs R
    J Med Chem; 2004 May; 47(10):2414-7. PubMed ID: 15115383
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and in vitro pharmacology of a series of new chiral histamine H3-receptor ligands: 2-(R and S)-Amino-3-(1H-imidazol-4(5)-yl)propyl ether derivatives.
    Kovalainen JT; Christiaans JA; Kotisaari S; Laitinen JT; Männistö PT; Tuomisto L; Gynther J
    J Med Chem; 1999 Apr; 42(7):1193-202. PubMed ID: 10197963
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis and structure-activity relationships of N-aryl-piperidine derivatives as potent (partial) agonists for human histamine H3 receptor.
    Ishikawa M; Furuuchi T; Yamauchi M; Yokoyama F; Kakui N; Sato Y
    Bioorg Med Chem; 2010 Jul; 18(14):5441-8. PubMed ID: 20541426
    [TBL] [Abstract][Full Text] [Related]  

  • 5. N(alpha)-imidazolylalkyl and pyridylalkyl derivatives of histaprodifen: synthesis and in vitro evaluation of highly potent histamine H(1)-receptor agonists.
    Menghin S; Pertz HH; Kramer K; Seifert R; Schunack W; Elz S
    J Med Chem; 2003 Dec; 46(25):5458-70. PubMed ID: 14640554
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis and structure-activity relationships of conformationally constrained histamine H(3) receptor agonists.
    Kitbunnadaj R; Zuiderveld OP; De Esch IJ; Vollinga RC; Bakker R; Lutz M; Spek AL; Cavoy E; Deltent MF; Menge WM; Timmerman H; Leurs R
    J Med Chem; 2003 Dec; 46(25):5445-57. PubMed ID: 14640553
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cyclopropane-based conformational restriction of histamine. (1S,2S)-2-(2-aminoethyl)-1-(1H-imidazol-4-yl)cyclopropane, a highly selective agonist for the histamine H3 receptor, having a cis-cyclopropane structure.
    Kazuta Y; Hirano K; Natsume K; Yamada S; Kimura R; Matsumoto S; Furuichi K; Matsuda A; Shuto S
    J Med Chem; 2003 May; 46(10):1980-8. PubMed ID: 12723960
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 4-benzyl-1H-imidazoles with oxazoline termini as histamine H3 receptor agonists.
    Wijtmans M; Celanire S; Snip E; Gillard MR; Gelens E; Collart PP; Venhuis BJ; Christophe B; Hulscher S; van der Goot H; Lebon F; Timmerman H; Bakker RA; Lallemand BI; Leurs R; Talaga PE; de Esch IJ
    J Med Chem; 2008 May; 51(10):2944-53. PubMed ID: 18433114
    [TBL] [Abstract][Full Text] [Related]  

  • 9. N-substituted piperidinyl alkyl imidazoles: discovery of methimepip as a potent and selective histamine H3 receptor agonist.
    Kitbunnadaj R; Hashimoto T; Poli E; Zuiderveld OP; Menozzi A; Hidaka R; de Esch IJ; Bakker RA; Menge WM; Yamatodani A; Coruzzi G; Timmerman H; Leurs R
    J Med Chem; 2005 Mar; 48(6):2100-7. PubMed ID: 15771452
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stereochemical diversity-oriented conformational restriction strategy. Development of potent histamine H3 and/or H4 receptor antagonists with an imidazolylcyclopropane structure.
    Watanabe M; Kazuta Y; Hayashi H; Yamada S; Matsuda A; Shuto S
    J Med Chem; 2006 Sep; 49(18):5587-96. PubMed ID: 16942032
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diether derivatives of homo- or substituted piperidines as non-imidazole histamine H3 receptor ligands.
    Łazewska D; Kuder K; Ligneau X; Camelin JC; Schunack W; Stark H; Kieć-Kononowicz K
    Bioorg Med Chem; 2009 Apr; 17(8):3037-42. PubMed ID: 19329325
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Meta-substituted aryl(thio)ethers as potent partial agonists (or antagonists) for the histamine H3 receptor lacking a nitrogen atom in the side chain.
    Pelloux-Léon N; Fkyerat A; Piripitsi A; Tertiuk W; Schunack W; Stark H; Garbarg M; Ligneau X; Arrang JM; Schwartz JC; Ganellin CR
    J Med Chem; 2004 Jun; 47(12):3264-74. PubMed ID: 15163206
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Piperidine variations in search for non-imidazole histamine H(3) receptor ligands.
    Łazewska D; Kuder K; Ligneau X; Schwartz JC; Schunack W; Stark H; Kieć-Kononowicz K
    Bioorg Med Chem; 2008 Sep; 16(18):8729-36. PubMed ID: 18774720
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A new potent and selective histamine H3 receptor agonist, 4-(1H-imidazol-4-ylmethyl)piperidine.
    Vollinga RC; de Koning JP; Jansen FP; Leurs R; Menge WM; Timmerman H
    J Med Chem; 1994 Feb; 37(3):332-3. PubMed ID: 8308858
    [No Abstract]   [Full Text] [Related]  

  • 15. A selective human H(4)-receptor agonist: (-)-2-cyano-1-methyl-3-[(2R,5R)-5- [1H-imidazol-4(5)-yl]tetrahydrofuran-2-y] methylguanidine.
    Hashimoto T; Harusawa S; Araki L; Zuiderveld OP; Smit MJ; Imazu T; Takashima S; Yamamoto Y; Sakamoto Y; Kurihara T; Leurs R; Bakker RA; Yamatodani A
    J Med Chem; 2003 Jul; 46(14):3162-5. PubMed ID: 12825954
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structural variations of 1-(4-(phenoxymethyl)benzyl)piperidines as nonimidazole histamine H3 receptor antagonists.
    Mikó T; Ligneau X; Pertz HH; Arrang JM; Ganellin CR; Schwartz JC; Schunack W; Stark H
    Bioorg Med Chem; 2004 May; 12(10):2727-36. PubMed ID: 15110854
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of the binding site of the histamine H3 receptor. 1. Various approaches to the synthesis of 2-(1H-imidazol-4-yl)cyclopropylamine and histaminergic activity of (1R,2R)- and (1S,2S)-2-(1H-imidazol-4-yl)-cyclopropylamine.
    De Esch IJ; Vollinga RC; Goubitz K; Schenk H; Appelberg U; Hacksell U; Lemstra S; Zuiderveld OP; Hoffmann M; Leurs R; Menge WM; Timmerman H
    J Med Chem; 1999 Apr; 42(7):1115-22. PubMed ID: 10197956
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel histamine H3 receptor antagonists based on the 4-[(1H-imidazol-4-yl)methyl]piperidine scaffold.
    Vaccaro WD; Sher R; Berlin M; Shih NY; Aslanian R; Schwerdt JH; McCormick KD; Piwinski JJ; West RE; Anthes JC; Williams SM; Wu RL; She HS; Rivelli MA; Mutter JC; Corboz MR; Hey JA; Favreau L
    Bioorg Med Chem Lett; 2006 Jan; 16(2):395-9. PubMed ID: 16246552
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 4-(omega-(alkyloxy)alkyl)-1H-imidazole derivatives as histamine H(3) receptor antagonists/agonists.
    Meier G; Krause M; Hüls A; Ligneau X; Pertz HH; Arrang JM; Ganellin CR; Schwartz JC; Schunack W; Stark H
    J Med Chem; 2004 May; 47(10):2678-87. PubMed ID: 15115409
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of hydrophobic substituents on the terminal nitrogen of histamine in receptor binding and agonist activity: development of an orally active histamine type 3 receptor agonist and evaluation of its antistress activity in mice.
    Ishikawa M; Shinei R; Yokoyama F; Yamauchi M; Oyama M; Okuma K; Nagayama T; Kato K; Kakui N; Sato Y
    J Med Chem; 2010 May; 53(9):3840-4. PubMed ID: 20384344
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.